Revolution Medicines · 1 day ago
Scientist II, Cancer Pharmacology, Translational Research
San Francisco Bay Area
Full-time
Hybrid
Entry, Mid Level
$128K/yr - $160K/yr
2+ years expRevolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. As a Scientist II in the Translational Research team, you will collaborate on quantitative modeling and oversee in vivo and ex vivo studies to support drug development projects.
Health CareLife ScienceMedical
Responsibilities
As a member of a cross-functional quantitative modeling group, collaborate with team members to develop, validate and refine physiologically-based PK (PBPK), quantitative systems pharmacology (QSP), and semi-mechanistic PK/PD models to support discovery and development-phase projects
Seek and apply innovative modeling approaches to understand tumor resistance to RAS(ON) inhibitors and build in silico models, propose mechanistic in vitro and in vivo experiments to test model assumptions and structure
Design and oversee in vivo and ex vivo studies (internally and via CROs), develop and maintain high-quality protocols and documentation, and present results at internal forums and scientific conferences
Qualification
Required
Ph.D. in pharmacology or cancer biology, or a quantitative discipline (pharmaceutical sciences, mathematics, systems pharmacology, computational biology, etc.) with direct relevance to drug development
2+ years of relevant postdoc or industry experience in cancer drug discovery and development
Demonstrated experience in in vivo experiments with oncology disease models
Solid PK/PD knowledge and prior experience with PK/PD data collection and analysis
A strong theoretical understanding of the core concepts, assumptions, and limitations associated with PK/PD mathematical modeling
Rigorous, quantitative and detail-oriented with proven excellence in experimental design, data analysis, data management, and presentation
Excellent written and verbal communication skills. Able to effectively communicate modeling assumptions, limitations, and simulation results to non-specialist and specialist audiences
Demonstrated ability to multi-task, prioritize options, anticipate challenges, and execute on goals as a member of an interdisciplinary team is extremely important
Thrives in a collaborative team setting and is driven by a desire to be innovative in a dynamic and fast-paced environment
Preferred
An understanding of preclinical to clinical translational concepts desired
Strong track record of research productivity as evidenced by high-quality, impactful publications
Experience with development, calibration, and validation of ordinary differential equation (ODE) and non-linear mixed effect (NLME) models
Hands on experience with modeling software (Simbiology, Phoenix WinNonlin, NONMEM, etc.) and PBPK model development
Benefits
Competitive cash compensation
Robust equity awards
Strong benefits
Significant learning and development opportunities
Company
Revolution Medicines
Revolution Medicines is an innovative and dynamic organization of expert biologists, chemists, pharmacologists, clinical scientists.
501-1000 employees
H1B Sponsorship
Revolution Medicines has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (13)
2024 (18)
2023 (15)
2022 (8)
2021 (1)
2020 (2)
Funding
Current Stage
Public CompanyTotal Funding
$2.25BKey Investors
Royalty PharmaBoxer CapitalNextech Invest
2025-06-24Post Ipo Debt· $250M
2024-12-02Post Ipo Equity· $750M
2023-03-02Post Ipo Equity· $323.6M
Leadership Team
Luan Wilfong
Chief Human Resources Officer
Steve Kelsey
President
Recent News
Pharmaceutical Technology
2026-01-13
Company data provided by crunchbase